Inovio Pharmaceuticals
Plymouth Meeting · Founded 1979
About Inovio Pharmaceuticals
INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with HPV, cancer, and infectious diseases. INOVIO is the first and only company to have clinically demonstrated that DNA medicine can be delivered directly into cells in the body via a proprietary smart device to produce a robust and tolerable immune response. Specifically, INOVIO's lead candidate VGX-3100, currently in Phase 3 trials for precancerous cervical dysplasia, demonstrated it destroyed and cleared high-risk HPV 16 and 18 in a Phase 2b clinical trial. High-risk HPV is responsible for 70% of cervical cancer, 90% of anal cancer, and 69% of vulvar cancer.
Company Facts
- Founded: 1979
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: Less than $1M
- Total funding: $579.9M
- Funding stage: IPO
- Last round: Post-IPO Equity (Apr 2026)
- Ticker: nasdaq:INO
- Website: inovio.com
- Phone: 267-440-4200
Industries & Categories
Biotechnology, Health Care, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/inovio-pharmaceuticals-57939 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.